Monitor for any strategic pivot under the new CEO, particularly around pipeline acceleration or business development given Sapirstein's commercialization background. No immediate catalyst — the appointment is a management refresh for a clinical-stage biotech with a $14M market cap.
Price Chart
Executive Summary
Cocrystal Pharma appointed James Sapirstein as CEO, effective immediately, replacing co-CEOs Sam Lee and Jim Martin. Lee becomes President/CSO and Martin remains CFO. Sapirstein brings antiviral development and commercialization experience from Gilead, Tobira, and Contravir.
Key Facts
- James Sapirstein appointed CEO effective June 3, 2026, replacing co-CEOs Sam Lee and Jim Martin
- Sam Lee transitions to President and Chief Scientific Officer; Jim Martin remains CFO
- Sapirstein has participated in or led 23 product launches and held senior roles at Gilead Sciences, Tobira Therapeutics, and Contravir Pharmaceuticals
- Company plans to appoint Sapirstein to the Board of Directors
- No financial terms, guidance, or material financial data disclosed in the filing
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- CEO transition risk — new leadership may shift pipeline priorities or strategy
- Clinical-stage biotech with no approved products; execution risk remains high
- No financial guidance or pipeline timeline updates provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-026965 |
| Exhibit: ex99-1.htm | 0001493152-26-026965 |
| Document: 0001493152-26-026965-index-headers.html | 0001493152-26-026965 |
| Document: 0001493152-26-026965-index.html | 0001493152-26-026965 |
| Document: 0001493152-26-026965.txt | 0001493152-26-026965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 8-K | $1.24 | awaiting T+60 | — | $0.9700 (−21.77%) |
Aug 3, 2026 12w ago | 8-K | $0.9400 | awaiting T+60 | — | $0.9700 (+3.19%) |
Jun 9, 2026 19w ago | 8-K | $1.02 $1.16 | ▲ +13.73% | ▲ +9.91% | $0.9700 (−4.90%) |
Jun 3, 2026 20w ago | 8-K | $1.06 $1.14 | ▲ +7.55% | ▲ +5.05% | $0.9700 (−8.49%) |
May 27, 2026 21w ago | DEFA14A | $1.13 $1.15 | ▲ +1.77% | ▲ +0.03% | $0.9700 (−14.16%) |
May 26, 2026 21w ago | 8-K | $1.13 $1.15 | ▲ +1.33% | ▼ −1.40% | $0.9700 (−14.16%) |
May 15, 2026 23w ago | Press Release | $1.20 $1.08 | ▼ −10.00% | ▼ −14.52% | $0.9700 (−19.17%) |
May 4, 2026 25w ago | EFFECT | $1.31 $0.8703 | ▲ +33.56% | ▲ +35.42% | $0.9700 (+25.95%) |
Apr 2, 2026 29w ago | 8-K | $1.51 $1.05 | ▼ −30.46% | ▼ −44.62% | $0.9700 (−35.76%) |
Mar 31, 2026 29w ago | 8-K | $1.01 $1.02 | ▲ +0.99% | ▼ −11.39% | $0.9700 (−3.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers